These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9950454)

  • 1. Mortality in the CHAOS trial.
    Mitchinson MJ; Stephens NG; Parsons A; Bligh E; Schofield PM; Brown MJ
    Lancet; 1999 Jan; 353(9150):381-2. PubMed ID: 9950454
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone and cardiovascular disease-recent controversy.
    Pais P
    Indian Heart J; 2008; 60(3):241-4. PubMed ID: 19240314
    [No Abstract]   [Full Text] [Related]  

  • 3. Mortality in the CHAOS trial. Cambridge Heart Antioxidant Study.
    Ness A; Smith GD
    Lancet; 1999 Mar; 353(9157):1017-8. PubMed ID: 10459945
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vitamin E treatment of patients with coronary disease (Cambridge Heart Antioxidant Study--CHAOS)].
    Mörike EM
    Dtsch Med Wochenschr; 1996 May; 121(21):A9. PubMed ID: 8646973
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-oxidant therapy for ischaemic heart disease: where do we stand?
    Stephens N
    Lancet; 1997 Jun; 349(9067):1710-1. PubMed ID: 9193375
    [No Abstract]   [Full Text] [Related]  

  • 6. [Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
    MMW Fortschr Med; 2004; 146 Suppl 1():6-7. PubMed ID: 15493409
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
    Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
    Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidant effects of combined vitamins C and E in acute myocardial infarction. The randomized, double-blind, placebo controlled, multicenter pilot Myocardial Infarction and VITamins (MIVIT) trial.
    Jaxa-Chamiec T; Bednarz B; Drozdowska D; Gessek J; Gniot J; Janik K; Kawka-Urbanek T; Maciejewski P; Ogórek M; Szpajer M;
    Kardiol Pol; 2005 Apr; 62(4):344-50. PubMed ID: 16059992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
    Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
    Fortschr Med; 1996 Mar; 114(8):91-8. PubMed ID: 8647574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic lipase deficiency delays atherosclerosis, myocardial infarction, and cardiac dysfunction and extends lifespan in SR-BI/apolipoprotein E double knockout mice.
    Karackattu SL; Trigatti B; Krieger M
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):548-54. PubMed ID: 16397139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of lower heart rate to mortality and the benefits of exclusive heart rate reduction in ischaemia.
    Cardiovasc J Afr; 2007; 18(5):338-40. PubMed ID: 17985037
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
    Einecke D
    MMW Fortschr Med; 2004 Mar; 146(13):4-5. PubMed ID: 15219114
    [No Abstract]   [Full Text] [Related]  

  • 13. Should angiotensin-converting enzyme inhibitors be used in all patients with coronary artery disease or restricted to those with a history of myocardial infarction or myocardial revascularization?
    Danchin N
    Arch Cardiovasc Dis; 2009 Feb; 102(2):81-3. PubMed ID: 19303573
    [No Abstract]   [Full Text] [Related]  

  • 14. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study.
    Ciszewski A; Bilinska ZT; Brydak LB; Kepka C; Kruk M; Romanowska M; Ksiezycka E; Przyluski J; Piotrowski W; Maczynska R; Ruzyllo W
    Eur Heart J; 2008 Jun; 29(11):1350-8. PubMed ID: 18187561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: One year perspective on COURAGE.
    Sedlis SP; Boden WE; Weintraub WS; Maron DS; O'Rourke RA; Berman DS; Mancini GB;
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):428. PubMed ID: 19133682
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
    Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
    Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute myocardial infarct].
    Soares-Costa JT
    Acta Med Port; 1998 May; 11(5):403-7. PubMed ID: 9951050
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacological aspects of secondary prevention post-MI].
    Schrör K
    Z Kardiol; 2004; 93 Suppl 1():I1-3. PubMed ID: 15021997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do fish oils or vitamin E reduce morbidity and mortality after myocardial infarction?
    Rand PJ; Schooff M
    J Fam Pract; 1999 Nov; 48(11):847-8. PubMed ID: 10907618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.